Drug Profile
Research programme: metal-protein-attenuating compounds - Alterity Therapeutics
Alternative Names: MPAC - Alterity Therapeutics; PBT 519; PBT3 series - Alterity Therapeutics; PBT4 series - Alterity TherapeuticsLatest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Prana Biotechnology
- Developer Alterity Therapeutics; Prana Biotechnology
- Class Quinazolinones
- Mechanism of Action Alpha-synuclein inhibitors; Dopamine modulators; Iron chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Age-related macular degeneration; Alzheimer's disease; Brain cancer; Neurodegenerative disorders; Parkinson's disease
Most Recent Events
- 28 Dec 2022 Discontinued - Preclinical for Brain cancer in Australia (unspecified route)
- 28 Dec 2022 Discontinued - Preclinical for Parkinson's disease in Australia (PO)
- 28 Dec 2022 Discontinued for Neurodegenerative disorders in Australia (unspecified route)